E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10020772 |
E.1.2 | Term | Hypertension |
E.1.2 | System Organ Class | 10047065 - Vascular disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study was to determine the single-dose pharmacokinetics (PK) of olmesartan medoxomil (OM) in pediatric subjects with hypertension between the ages of 12 months to 16 years |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Age 12 months to 16 years, inclusive
2. Signed parental/guardian informed consent provided and assent from the subject if he/she was ≥ 7 years old, or as required by the local IRB.
3. Glomerular filtration rate (GFR) ≥ 30 mL/min/1.73 m2, estimated using the Schwartz equation
4. Sexually active females of child-bearing potential must have been practicing an acceptable method of birth control as defined as oral, injectable, or implantable hormonal contraceptives, intrauterine device, diaphragm plus spermicide, or female condom plus spermicide.
5. Negative serum beta-hCG at Screening and at administration (females of child bearing potential only)
6. Hypertension defined as one of the following:
- Current treatment for hypertension
- Systolic blood pressure (SBP) ≥ 95th percentile
- SBP or diastolic blood pressure (DBP) ≥ 90th percentile if diabetic or with a family history of hypertension |
|
E.4 | Principal exclusion criteria |
1. Clinically significant cardiac, gastrointestinal, hematological, hepatic or hepatobiliary, neurological, or pulmonary (except asthma) disorder
2. History of severe or symptomatic hypertension associated with stroke, seizures, encephalopathy, or other significant neurological findings within 2 years prior to Screening
3. Current treatment with more than 2 antihypertensive medications
4. Secondary hypertension from uncorrected coarctation of the aorta, bilateral renal artery stenosis, or unilateral renal artery stenosis in a single kidney
5. Serum albumin < 2.5 g/dL
6. Major organ or bone marrow transplantation except for kidney transplantation at least 6 months prior to Screening with stable renal function meeting the inclusion criteria
7. History of classic allergic response to the angiotensin II receptor antagonist class of drugs
8. Pregnancy or current lactation
9. Pertinent electrolyte disorders (serum sodium ≤ 130 mEq/L, potassium ≥ 5.5 mEq/L, for example)
10. Significant systemic disease that, in the judgment of the investigator, would disqualify the subject for this study
11. History of drug or alcohol abuse
12. Current treatment with any of the following medications: anticonvulsants, bile acid sequestrants, metoclopramide, major psychotropic agents, glucocorticosteroids (high-dose regimens, i.e., > 1 mg/kg given daily), prokinetic agents such as bethanechol or cisapride, antibiotics, except as approved by the Sponsor, any drug that might interfere with the absorption of OM
13. Any laboratory value at Screening outside the range of normal limits for the appropriate age group unless approved by the Principal Investigator and Sponsor
14. History of malignancy or exposure to cytotoxic agents within the last 6 months
15. Participation in another investigational new drug research study in the previous 30 days |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Pharmacokinetic endpoints |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
|
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 4 |
E.8.9.2 | In all countries concerned by the trial days | 9 |